Considering the limited efficacy of the available therapies in recurrent/metastatic disease and the poor prognosis of patients with cervical cancer progressing after first-line treatment, the approval of tisotumab vedotin could be practice-changing in the treatment landscape of this disease, regardless of TF expression, histology, or prior treatment. Here, TF is linked to cervical cancer.